Shire of the UK has posted a 35% rise in revenues to $608.7 million forthe third quarter with its old attention deficit hyperactivity disorderdrug Adderall XR and its follow-up Vyvanse showing much promise.

Netincome fell 60.2% to $34.7 million, though the decline was principallydue to $75.0 million paid out to Renovo in order to seal the rights toJuvista (human recombinant transforming growth factor beta-3), whichwill go into Phase III next year as an anti-scarring treatment.

Backto the sales and Adderall XR (mixed amphetamine salts) beat analysts’estimates and rose 20% to $249.0 million, while the latter’sheir-apparent, Vyvanse (lisdexamfetamine dimesylate), launched in July,brought in $10.6 million. Chief executive Matthew Emmens said thatthere has been “a very positive response to Vyvanse from physicians andpatients who have commented on the benefits this new chemical entityoffers” and its “consistent and effective control of ADHD symptomsthroughout the day”.

On a conference call, Mr Emmens said thatVyvanse is not only taking market share from Adderall XR, which willface generic competition in 2009, but also from competitors “which isvery encouraging''. Shire’s shares fell sharply recently amid fearsthat the switch to Vyvanse was a bit slow but analysts at MorganStanley issued a note saying that the firm is making good progress interms of positioning Vyvanse as a new drug with significant advantagesover Adderall XR and other ADHD products, adding that “we arecomfortable with the launch progress”.

As for Shire’s othertreatments, the ADHD patch product Daytrana (methylphenidate), fell 5%to $9.4 million, due in part to a provision made for returns followingthe voluntary market withdrawal of a limited quantity of the patches.Sales of Elaprase (idursulfase) for Hunter syndrome, launched in August2006, reached $55.1 million, while turnover from Fosrenol (lanthanumcarbonate) for high blood phosphate levels soared 135% to $28.7million, benefiting from new launches in Europe. Replagal (agalsidasealfa), for the treatment of Fabry disease, contributed $40.7 million tothe coffers, up 26%, while the ulcerative colitis therapy Pentasa(mesalamine) was up 18% to $43.7 million.

Mr Emmens concluded bynoting that the Basingstoke-based firm has raised its forecast for 2007revenues, which are now expected to grow at least 30%, compared with anearlier estimate of 25% growth.